Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


ThromboGenics Delays Diabetic Retinopathy Study; On Track To File Ocriplasmin For Retinal Adhesions

This article was originally published in The Pink Sheet Daily

Executive Summary

Belgian company focuses on filing orciplasmin for U.S. and EU approval, and preparing for commercialization.

You may also be interested in...

ThromboGenics Takes Its Time On Solo Launch Of Eye Drug Jetrea

Having taken a conservative approach to its first commercial launch, ThromboGenics plans to roll out newly approved eye drug Jetrea (ocriplasmin) in January 2013. Company is now recruiting a sales force to target retinal specialists, who are already well aware of the new drug.

Eyeing Solo U.S. Debut, EU Biotech ThromboGenics Preps Ocriplasmin For Launch

Small European biotechs usually build their business in their home region first, and later look to the US for growth. Belgium's ThromboGenics is doing the opposite; it aims to launch its lead product initially in the US, and will tackle Europe after partner and market leader Alcon paves the way.

Alcon Grabs Ex-U.S. Rights To ThromboGenics' Retina Adhesion Therapy Ocriplasmin In $500 Mil. Deal

Novartis' ophthalmic unit Alcon will collaborate with Belgium's ThromboGenics on the marketing and future development of the vitreomacular adhesion therapy, ocriplasmin.

Related Content


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts